Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus LOSARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus LOSARTAN.
BENICAR HCT vs Losartan
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Losartan is an angiotensin II receptor blocker (ARB) that selectively and competitively inhibits the binding of angiotensin II to the AT1 receptor, thereby antagonizing vasoconstriction, aldosterone secretion, and renal sodium reabsorption, leading to reduced blood pressure.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Losartan 50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.
None Documented
None Documented
Clinical Note
moderateLosartan + Etacrynic acid
"The risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid."
Clinical Note
moderateLosartan + Furosemide
"The risk or severity of adverse effects can be increased when Losartan is combined with Furosemide."
Clinical Note
moderateLosartan + Bumetanide
"The risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide."
Clinical Note
moderateLosartan + Benzydamine
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Terminal half-life: 6-9 hours (losartan), 6-9 hours (active metabolite E-3174); clinical context: once-daily dosing is sufficient due to prolonged receptor binding
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Renal: 50% (parent drug and active metabolite), Biliary/Fecal: 50%
Category C
Category D/X
ARB + Thiazide Diuretic
ARB
"The risk or severity of adverse effects can be increased when Losartan is combined with Benzydamine."